Research programme: dual-variable domain immunoglobulins - AbbVie

Drug Profile

Research programme: dual-variable domain immunoglobulins - AbbVie

Alternative Names: Dual-variable domain Ig; DVD-Ig™

Latest Information Update: 27 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Immunoglobulins; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Interleukin 1 alpha inhibitors; Interleukin 1 beta inhibitors; Interleukin-17 inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Osteoarthritis; Rheumatoid arthritis

Most Recent Events

  • 27 Aug 2015 Preclinical development is underway in USA
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to a new company called AbbVie
  • 08 Nov 2011 Preclinical pharmacodynamics data in Osteoarthritis presented at the 75th American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top